This is unpublished
ctdna study
The MC3 Institute is developing a randomized clinical trial to evaluate whether immune checkpoint inhibition (ICI) should be initiated when circulating tumor DNA (ctDNA) becomes positive, before an MCC recurrence becomes clinically evident. We will determine whether this approach improves patient outcomes, including progression-free survival and MCC-specific survival. We are seeking participation from other centers in this planning phase.
SINGLE-FRACTION RADIATION THERAPY
The MC3 Institute is planning to evaluate the efficacy of postoperative Single-Fraction Radiation Therapy (SFRT) compared to 5-week conventional Radiation Therapy (cRT) and observation groups for Stage I-II MCC patients at low-to-moderate risk of recurrence.
recurrence risk calculator
The MC3 Institute is seeking collaborators for a multi-center study aimed at validating and improving the Merkel Cell Carcinoma (MCC) recurrence risk calculator